new jefferies report - a biased view lol, page-21

Thanks Snork its a very good read with come very interesting sales projections attached.

We now have a line of products and that each product could be stand alone companies as it was said at the SYD meeting, for example the Autoinfusers revenue $250m gross margin of 70% in FY17....WOW!!

Although early in the launch phase, these device additions carry significant revenue
potential given the substantially higher unit ASP ranges relative to the company’s prefilled
syringe devices, particularly in regards to the auto-infusors. For the auto-injectors, Unilife
is targeting an ASP range of $3-$5 per unit; however, this device will also include an
embedded Unifill syringe bringing the total device ASP range to $4-$6 per unit. Due to
the complexities of the manufacturing process for the device and the targeted drug
classes the Unifill Auto-Infusor will be the company’s highest priced product at an ASP
range of $25-$50 per unit. Importantly, the company’s self-administration devices can be
filled at the time of use thereby eliminating the need for stability testing for clinical trial
purposes. Our current model forecasts three commercial deals for Unilife self-
administration devices (two auto-injectors and one auto-infusor) by the end of 2015.